Drug Trial Radar · NCT07154706
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Aug 21, 2025
Primary completion
Aug 30, 2030
Study completion Aug 30, 2033
Sponsor
- Lead sponsor
- Nuvation Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC. The study will evaluate if taletrectinib is better than placebo at preventing the participant's disease from coming back after the participant's lung tumor was removed.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
TaletrectinibDrug
Intervention Label: Taletrectinib Intervention Name: Taletrectinib Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level (s): 400 mg QD Route of Administration: Oral Use: Experimental IMP and NIMP/AxMP : IMP Former Name(s) or Alias(es): AB-106.
PlaceboDrug
Intervention Label: Placebo Intervention Name: Placebo Type: Drug Dosage Formulation: Capsule Unit Dose Strength(s): 200 mg Dosage Level(s): 400 mg QD Route of Administration: Oral Use: Placebo Comparator IMP and NIMP/AxMP: IMP Former Name(s) or Alias(es): Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Outcome Measure: To compare the efficacy of taletrectinib with that of placebo, as measured by disease-free survival (DFS) by investigator assessment.Time frame: Time Frame: Up to approximately 5 years after the first patient is randomized (maximum follow-up of 70 months).
Locations
33 sites in 3 countries. Site status is shown where the registry gives one.
UCLA
Los Angeles, California · Recruiting
UCI Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Georgetown University Medical Cener (GUMC)
Washington D.C., District of Columbia · Recruiting
Advent Health
Orlando, Florida · Recruiting
Saint Alphonsus Health System
Boise, Idaho · Recruiting
Tulane Cancer Center
New Orleans, Louisiana · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South
Austin, Texas · Recruiting
MD Anderson
Houston, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Princess Margaret Cancer Centre-University Health Network
Toronto, Ontario, Canada · Recruiting
McGill University
Montreal, Quebec, Canada · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangzhou, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Tongji Hospital Tongji Medical College of HUST
Wuhan, Hubei, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
Nantong Tumor Hospital
Nantong, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Linyi Cancer Hospital
Linyi, Shandong, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Tianjin Chest Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.